Peginterferon Alfa-2a Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose Stratified by Rapid Virologic Response.
Phase of Trial: Phase IV
Latest Information Update: 03 Jun 2014
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Mar 2013 Actual initiation date changed from Jun 2006 to Nov 2007 as reported by ClinicalTrials.gov.
- 19 Dec 2012 Planned number of patients changed from 700 to 962 as reported by ClinicalTrials.gov.